Vyteris wants to give up drug-delivery ghost

The drug-delivery business isn't for everybody. And New Jersey-based Vyteris wants out, according to an article on in-PharmaTechnologist. Vyteris is hanging a "for sale" sign on its adhesive, patch-based technology platform. The future for Vyteris, the company says, is in acquiring contract research organizations. Vyteris no doubt does see CROs as a good investment, but, as in-PharmaTechnologist points out, there's probably more to the story. "However, while recognition of these trends was undoubtedly a motivation, Vyteris' decision to refocus as a CRO also reflects the difficulties it has had with its delivery technology business," the article says. Read it all here

Suggested Articles

Takeda forged a feasibility pact to see whether it could pair a plasma-based therapy with Elektrofi's microparticle delivery tech.

RNA nanoparticles can squeeze into tumors and exit swiftly through the kidney, perfect for targeted delivery of cancer drugs, an OSU team says.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.